Showing results (121-130 of 251) with videos related to
Sort By:
Pageof 26
Cancer Science|June 15, 2018
Isolation and molecular analysis of circulating tumor cells from lung cancer patients using a microfluidic chip type cell sorterMasaru Watanabe, Hirotsugu Kenmotsu, Ryo Ko, et al.Lung Cancer (Amsterdam, Netherlands)|June 23, 2009
Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancerKyoichi Kaira, Tateaki Naito, Toshiaki Takahashi, et al.Drugs in R&D|December 17, 2020
Safety and Antitumor Activity of Repeated ASP3026 Administration in Japanese Patients with Solid Tumors: A Phase I StudyAkira Ono, Haruyasu Murakami, Takashi Seto, et al.International Journal of Clinical Oncology|March 19, 2022
Multi-institutional feasibility study of intensity-modulated radiotherapy with chemotherapy for locally advanced non-small cell lung cancerHideyuki Harada, Shota Omori, Keita Mori, et al.Investigational New Drugs|April 8, 2015
The efficacy of amrubicin on central nervous system metastases originating from small-cell lung cancer: a case series of eight patientsSatoru Miura, Kyoichi Kaira, Rieko Kaira, et al.Investigational New Drugs|October 26, 2024
A phase II study of ME2136 (Asenapine Maleate) plus standard antiemetic therapy for patients, including diabetic patients, receiving cisplatin-based chemotherapySatoshi Hamauchi, Hirofumi Yasui, Tomoya Yokota, et al.Investigational New Drugs|January 18, 2012
Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumorsToshiaki Takahashi, Narikazu Boku, Haruyasu Murakami, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2016
Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor MutationsYing Cheng, Haruyasu Murakami, Pan-Chyr Yang, et al.Cancer Chemotherapy and Pharmacology|July 13, 2022
Prospective evaluation of the relationship between response and exposure of total and unbound erlotinib in non-small cell lung cancer patientsHirotsugu Kenmotsu, Chiyo K Imamura, Takahisa Kawamura, et al.Thoracic Cancer|January 15, 2016
Differences in the efficacy of S-1 monotherapy according to histological type in pretreated patients with advanced non-small cell lung cancerYasushi Hisamatsu, Haruyasu Murakami, Hiroaki Akamatsu, et al.Pageof 26